Claritev Corporation (CTEV)

Ligand Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	935.54	930.62	961.52	1,080	1,118	937.76
Revenue Growth (YoY)	-2.03%	-3.21%	-10.95%	-3.39%	19.18%	-4.59%
Cost of Revenue	239.22	239.4	235.47	204.1	175.29	318.68
Gross Profit	696.32	691.22	726.06	875.62	942.31	619.09
Selling, General & Admin	178.73	160.22	135.99	132.14	141.45	323.15
Operating Expenses	617.81	592.29	556.01	541.44	546.54	718.42
Operating Income	78.52	98.93	170.05	334.18	395.77	-99.33
Interest Expense	-354.43	-326.37	-333.21	-303.4	-267.48	-335.64
Interest & Investment Income	2.46	3.13	8.23	3.79	0.06	0.29
Other Non Operating Income (Expenses)	-71.72	-63.45	1.97	67.05	32.6	35.42
EBT Excluding Unusual Items	-345.17	-287.76	-152.96	101.62	160.94	-399.26
Merger & Restructuring Charges	-15.65	-	-8.06	-34.69	-9.65	-32.49
Impairment of Goodwill	-355.81	-1,426	-	-657.92	-	-
Gain (Loss) on Sale of Investments	-	-	-	-	-	-12.17
Asset Writedown	-60.3	-63	-	-4.3	-	-
Other Unusual Items	-0.67	5.91	53.97	34.55	-15.84	-102.99
Pretax Income	-777.6	-1,771	-107.06	-560.74	135.45	-546.91
Income Tax Expense	-114.23	-124.88	-15.36	12.17	33.37	-26.34
Net Income	-663.37	-1,646	-91.7	-572.91	102.08	-520.56
Net Income to Common	-663.37	-1,646	-91.7	-572.91	102.08	-520.56
Shares Outstanding (Basic)	16	16	16	16	16	12
Shares Outstanding (Diluted)	16	16	16	16	16	12
Shares Change (YoY)	0.47%	0.12%	0.97%	-1.93%	38.39%	13.25%
EPS (Basic)	-40.80	-101.92	-5.69	-35.87	6.27	-44.23
EPS (Diluted)	-40.80	-101.92	-5.69	-36.00	6.27	-44.40
Free Cash Flow	-55.01	-10.51	62.87	282.63	320.1	306.56
Free Cash Flow Per Share	-3.38	-0.65	3.90	17.69	19.65	26.05
Gross Margin	74.43%	74.28%	75.51%	81.10%	84.31%	66.02%
Operating Margin	8.39%	10.63%	17.69%	30.95%	35.41%	-10.59%
Profit Margin	-70.91%	-176.85%	-9.54%	-53.06%	9.13%	-55.51%
Free Cash Flow Margin	-5.88%	-1.13%	6.54%	26.18%	28.64%	32.69%
EBITDA	517.6	531.01	590.06	743.47	800.86	295.94
EBITDA Margin	55.33%	57.06%	61.37%	68.86%	71.66%	31.56%
D&A For EBITDA	439.08	432.07	420.02	409.29	405.1	395.27
EBIT	78.52	98.93	170.05	334.18	395.77	-99.33
EBIT Margin	8.39%	10.63%	17.69%	30.95%	35.41%	-10.59%
Effective Tax Rate	-	-	-	-	24.64%	-

Updated Aug 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q